No CrossRef data available.
Article contents
An audit of risperidone long acting injection in Lincolnshire, UK
Published online by Cambridge University Press: 16 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Risperidone long acting injection (RLAI) is the first injectable atypical antipsychotic to be licensed in the UK. This study reports the outcomes of patients prescribed RLAI in Lincolnshire Partnership Trust during two years period following its launch.
Aim and methodology:
That RLAI are prescribed appropriately and patients are monitored on an ongoing basis. An audit tool was sent to each psychiatrist, data were collected retrospectively on 28 patients.
Results:
Out of 28 patients 19 still taking RLAI. Data not available on one patient. All patients had received oral atypical prior to RLAI. 23 were exposed to oral Risperidone. 80% reported significant improvement only 5 experienced mild side effects. 21 suffered from Schizophrenia and 6 from Bipolar Affective Disorder. At the time of initiation, 25 in patients and 3 in community. Significant improvement noted 2 months and 7 months after initiation. All of them were monitored regularly.
Conclusions:
RLAI appears well tolerated and markedly effective in vast majority of patients only 3 patients showed negative response. RLAI can offer considerable benefit to a significant number of patients suffering from Schizophrenia and Bipolar Affective Disorder with psychotic symptoms.
- Type
- Poster Session 1: Antipsychotic Medications
- Information
- European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S168
- Copyright
- Copyright © European Psychiatric Association 2007
You have
Access
Comments
No Comments have been published for this article.